Strategic partnerships Leverage Zenas’ strong late-stage pipeline and collaboration history, such as the InnoCare partnership and Royalty Pharma funding, to identify co-development or licensing opportunities that accelerate global commercialization and expand product access.

CD19 and BTK franchise Target partnerships around obexelimab and orelabrutinib due to their high-profile mechanisms (CD19/FcγRIIb–mediated activity and CNS-penetrant BTK inhibition) with potential for rapid tier-1 clinical adoption and milestone-based monetization.

_autoimmune focus Position offerings to biotech investors and pharma buyers emphasizing a leadership role in autoimmune diseases, with a diversified pipeline (late-stage and preclinical) to mitigate risk and provide multiple commercialization windows.

Commercial readiness cues Capitalize on recent NEJM publication and NEuropa/EULAR data to support value-based discussions, payer strategies, and market access planning for obexelimab and orelabrutinib in autoimmune indications.

Funding leverage Explore co-development, milestone, and royalty-based deals leveraging existing $813M funding and up to $300M royalty commitments to de-risk launches and secure capital for expansion and global commercialization.